FAKTOR-OPTIONSSCHEIN - INCYTE CO. | Real-time Boerse Frankfurt Warrants 01:20:54 03/07/2024 pm IST | ||
| 10.07 EUR | -1.18% |
|
| Current month | +3.14% | ||
| 1 month | -4.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 10.07 | -1.18% |
| 02/24/02 | 10.19 | +6.37% |
| 01/24/01 | 9.58 | -3.04% |
| 28/24/28 | 9.88 | +3.78% |
| 27/24/27 | 9.52 | +1.38% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 01:20 pm IST
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SD416V |
| ISIN | DE000SD416V0 |
| Date issued | 29/03/2021 |
| Strike | 79.94 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.48 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.08 € |
|---|---|
| Lowest since issue | 5.31 € |
| Spread | 0.37 € |
| Spread % | 3.55% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
59.02
USD
Average target price
72.62
USD
Spread / Average Target
+23.04%
- Stock Market
- Certificates
- Certificat
